BioMed Realty Trust (BioMed Realty Trust) Cash And Cash Equivalents : $48.7 Mil (As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is BioMed Realty Trust Cash And Cash Equivalents?

BioMed Realty Trust's quarterly cash and cash equivalents declined from Mar. 2015 ($64.96 Mil) to Jun. 2015 ($45.33 Mil) but then increased from Jun. 2015 ($45.33 Mil) to Sep. 2015 ($48.68 Mil).

BioMed Realty Trust's annual cash and cash equivalents increased from Dec. 2012 ($19.98 Mil) to Dec. 2013 ($34.71 Mil) and increased from Dec. 2013 ($34.71 Mil) to Dec. 2014 ($46.66 Mil).

BioMed Realty Trust Cash And Cash Equivalents Historical Data

The historical data trend for BioMed Realty Trust's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMed Realty Trust Cash And Cash Equivalents Chart

BioMed Realty Trust Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Cash And Cash Equivalents

Get a 7-Day Free Trial

21.47

16.41

19.98

34.71

46.66

BioMed Realty Trust Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
Cash And Cash Equivalents	Get a 7-Day Free Trial															33.86	46.66	64.96	45.33	48.68

BioMed Realty Trust Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BioMed Realty Trust (NYSE:BMR) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BioMed Realty Trust Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioMed Realty Trust's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMed Realty Trust (BioMed Realty Trust) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » REITs » BioMed Realty Trust Inc (NYSE:BMR) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.biomedrealty.com

BioMed Realty Trust Inc, a Maryland corporation was formed on April 30, 2004 and commenced operations on August 11, 2004, after completing its initial public offering. The Company operates as a self-administered and self-managed real estate investment trust focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry mainly through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership Its tenants mainly include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are generally located in markets with well established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/ New Jersey. The Company faces competition from various entities for investment opportunities in properties for life science tenants, including other REITs, such as health care REITs and suburban office property REITs, pension funds, insurance companies, investment funds and companies, partnerships, and developers. The Company's properties are subject to various laws, ordinances and regulations, including regulations relating to common areas.

Executives

Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Brody William R Md Phd	director	MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Janice L. Sears	director	1100 PARK PLACE, SUITE 200, SAN MATEO CA 94403
Alan D Gold	director, officer: Chairman, President and CEO	17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Gary A Kreitzer	director, officer: Exec VP and Assistant Sec	17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Margaret Faye Wilson	director	12836 LUNADA PLACE, SAN DIEGO CA 92128
Griffin R Kent Jr	officer: President and COO	5950 SHERRY LANE, SUITE 700, DALLAS TX 75225
Richard I Gilchrist	director	5950 SHERRY LANE, SUITE 700, DALLAS TX 75225